Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-iNKT Cells for Relapsed/Refractory/High-risk B-cell Tumors
NCT04814004Phase 1Unknown
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 chimeric antigen receptor invariant natural killer T cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and B cell lymphoma. Primary endpoint: Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
anti-CD19 chimeric antigen receptor invariant natural killer T cells
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)B cell lymphoma
Beyond the preview
Go deeper on NCT04814004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814004.